Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

65 results about "Protective immunity" patented technology

Protective immunity is the body’s ability to resist a certain disease. The body’s source of protective immunity against microbes comes from the antibodies created by B cells, as well as the memories stored in the body’s specialized lymphocytes (B and T cells).

CoV-2 (CoV-n) antibody neutralizing and CTL vaccines using protein scaffolds and molecular evolution

The embodiment of the invention is to conformationally constrain neutralizing B cell epitopes of CoV-2, CoV-n B cell epitopes of the open reading frame proteins, including the membrane S protein, constrained by protein scaffolds, including camelid VHH nanobody in order to elicit neutralizing and blocking antibodies against viral infection. B cell epitopes are molecularly evolved by ribosome display to preempt emerging viral B cell epitopes. Moreover, CTL epitopes are designed from the open reading frame protein for eliciting cell mediated viral protection. Furthermore, mRNA vaccines are prepared for eliciting protective immunity and prevent cytokine storms.
Owner:CHEN SWEY SHEN

Varicella-zoster vaccine composition and use thereof

PCT designated stage expiredWO2025113554A1Viral antigen ingredientsAntiviralsAdjuvantNucleotide
A varicella-zoster vaccine composition and use thereof, belonging to the technical field of biological vaccines. The composition comprises a VZV gE antigen and a CpG ODN adjuvant and further comprises an aluminum adjuvant. The nucleotide sequence of the CpG ODN adjuvant is set forth in SEQ ID NO: 1. The CpG ODN adjuvant with a specific nucleotide sequence has better immunostimulatory activity. The provided varicella-zoster vaccine composition can generate a higher humoral immune response earlier and induce protective immunity in advance for at least one month. One immunization can reach or be close to the antibody level of two immunizations of the Shingrix vaccine. Moreover, the longer-time stable high-humoral immunity level can be kept, and cellular immunity can also be generated.
Owner:HUAPU SHIJIAZHUANG PHARMACEUTICAL CO LTD

Varicella zoster vaccine composition and application thereof

The invention discloses a varicella zoster vaccine composition and application thereof, and belongs to the technical field of biological vaccines, the composition comprises a VZV gE antigen, a CpG ODN adjuvant and an aluminum adjuvant, and the nucleotide sequence of the CpG ODN adjuvant is shown as SEQ ID NO: 1. According to the invention, the CpG ODN adjuvant with a specific nucleotide sequence is selected, so that the immunostimulatory activity is better; the varicella zoster vaccine composition provided by the invention can generate high humoral immune response earlier, and induces protective immunity for at least one month in advance; the antibody level of twice immunization of a Shigrix vaccine can be reached or close to once immunization, the stable high humoral immune level for a long time can be kept, and meanwhile cellular immunity can be generated.
Owner:HUAPU SHIJIAZHUANG PHARMACEUTICAL CO LTD

Broad-spectrum multi-antigen pan-coronavirus vaccine

Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen / LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.
Owner:RGT UNIV OF CALIFORNIA

Immunoactive composition and pertussis vaccine containing same

The invention belongs to the technical field of biology, and relates to an immunocompetence composition and a pertussis vaccine containing the immunocompetence composition. The immunocompetence composition comprises pertussis Bordetella outer membrane vesicles and attenuated pertussis toxins in a weight ratio of (5-50): (5-25). Effective protective immunity can be triggered in the process of preventing pertussis infection, pertussis bacteria in the lung are effectively eradicated, and bacterial colonization in the trachea and the nasal cavity is remarkably reduced.
Owner:SUZHOU JUWEI BIOTECH CO LTD

A multi-stage vaccine antigen for malaria

The present disclosure provides a recombinant antigen which is capable of eliciting protective immunity against all three stages of the Plasmodium life cycle, as well as compositions for and methods of preventing or inhibiting primary infection, disease severity, and transmission of malaria.
Owner:SEATTLE CHILDRENS HOSPITAL (DBA SEATTLE CHILDRENS RES INST)

Immunocontraception vaccines and methods for production

Disclosed herein are recombinant poxvirus vectors, compositions, and methods for inducing immune responses in animals, particularly for vaccination against infectious diseases and for immunocontraception. Poxviruses, preferably species-specific and attenuated poxviruses such as Swinepox Virus (SWPV) for swine, are engineered to express heterologous nucleic acid sequences encoding one or more desired polypeptides to express one or a plurality of African Swine Fever Virus (ASFV) antigens for inducing protective immunity against ASFV in swine. Further, the recombinant poxviruses express immunocontraceptive antigens, such as Gonadotropin-Releasing Hormone (GnRH) often as a fusion protein with a carrier like Maltose-Binding Protein or flagellin, to induce infertility for humane animal population control in various animal species.
Owner:THE AMBER & ADAM TARSHIS FOUNDATION

Methods of manufacturing porcine endogenous retrovirus (PERV) free animal health vaccines

The invention provides a method of preparing a vaccine composition. The method includes infecting gene-edited porcine endogenous retrovirus (PERV) negative swine cells with a microorganism which expresses at least one protein antigen capable of inducing protective immunity in an animal against an infectious agent; culturing the infected cells in culture medium to propagate the microorganism; and harvesting the propagated microorganism from the culture medium to obtain a fraction comprising a PERV free antigen for use in immunizing an animal against the infectious agent.
Owner:ZOETIS SERVICES LLC

Oral vaccine against multiple diarrhea-causing pathogens

PCT designated stageWO2026041729A1Digestive systemMultivalent vaccineShigella spAntigen
A vaccine comprising effective amounts of i) E. coli colonization factor antigens comprising CFA / I, CS3, CS5 and CS6 antigens; ii) a heat labile enterotoxin B subunit antigen being an LCTBA protein; and iii) an adjuvant being double mutant (R192G / L211A) of E. coli heat-labile toxin (dmLT), for use in inducing protective immunity against diarrheal disease caused by Salmonella spp. and / or Shigella spp.
Owner:SCANDINAVIAN BIOPHARMA HOLDING AB

Methods of manufacturing porcine endogenous retrovirus (PERV) free animal health vaccines

The invention provides a method of preparing a vaccine composition. The method includes infecting gene-edited porcine endogenous retrovirus (PERV) negative swine cells with a microorganism which expresses at least one protein antigen capable of inducing protective immunity in an animal against an infectious agent; culturing the infected cells in culture medium to propagate the microorganism; and harvesting the propagated microorganism from the culture medium to obtain a fraction comprising a PERV free antigen for use in immunizing an animal against the infectious agent.
Owner:ZOETIS SERVICES LLC

Induction of protective immunity against antigens

Described herein are compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and / or regulated expression of one or more antigens from Clostridium Perfringens as vaccines to prevent necrotic enteritis (NE).
Owner:UNIV OF FLORIDA RESEARCH FOUNDATION INC

Rationally designed single-round infectious virus and methods of use thereof

Engineered, replication-deficient influenza viruses that are infectious and stimulate broadly-cross protective immunity against multiple different influenza strains have been developed. Compositions and methods for providing protective immune responses against influenza are provided. The methods deliver compositions of intact, replication-deficient influenza viruses by intradermal administration in an amount effective to elicit or stimulate a cross-protective immune response to influenza viruses in the recipient following a single administration. Because the engineered influenza viruses are non-replicating, they are safe and effective in immunocompromised subjects. Methods for delivering co-stimulatory molecules, growth factors, adjuvants and / or cytokines together with the non-replicating influenza viruses are also provided.
Owner:VERSITECH LTD +1

Methods and compositions for vaccinating piglets against PRRS-1 virus

The present disclosure provides a vaccine comprising a modified live PRRS-1 virus attenuated in a cell expressing porcine CD163 for inducing protective immunity in a piglet of 60 hours old or more wherein the vaccine is intranasally administered to the piglet.
Owner:ZOETIS SERVICES LLC

Immunization against group a streptococcus (GAS)

A composition comprising isolated Streptococcus pyogenes extracellular vesicles (EVs) suspended in a vehicle, for use in eliciting an adaptive immune response against group A streptococcus (GAS) in a subject. The EVs may comprise antigens MtsA, Spy_1228, PrsA1, PrsA2, SPy_0319 and / or GlnP. A composition comprising isolated S. pyogenes protein(s) MtsA, SPy_1228, PrsA1, PrsA2, GlnP, SPy_0319 and / or MalX. The compositions may be used for inducing protective immunity in a subject against a GAS infection, such as streptococcal pharyngitis, scarlet fever, impetigo, streptococcal meningitis, streptococcal sinusitis, necrotizing fasciitis, cellulitis, streptococcal toxic shock syndrome, rheumatic fever and post-streptococcal glomerulonephritis.
Owner:HENRIQUES NORMARK BIRGITTA

Vesicular stomatitis virus lassa virus vaccine

Lassa fever is a zoonotic viral hemorrhagic disease caused by Lassa virus (LASV), endemic in multiple west African countries where the multimammate rat is a main virus reservoir. The broad geographic range of the rodent host places a large population at risk of serious illness. LASV is also a bioterrorism threat. A LASV vaccine is an unmet need. Applicants advance a vaccine based on a live vesicular stomatitis virus vector for immunizing against the LASV surface glycoprotein. Preclinical evaluation exhibited high efficacy in cynomolgus macaques. The animals developed serum antibodies that could mediate antiviral effector functions including direct neutralization of virus infectivity. This vaccine candidate elicited robust protective immunity in cynomolgus macaques that prevented development of detectable viremia and disease for at least 1 year after vaccination. These protective immune response features provide valuable data for comparison to an ongoing phase 1 clinical trial and planned phase 2b / 3 clinical trials.
Owner:INTERNATIONAL AIDS VACCINE INITIATIVE INC

Recombinant modified saRNA (VRP) and vaccinia virus Ankara (MVA) prime-boost regimen

The present invention provides compositions, vaccines, and methods for inducing protective immunity to immunogens in humans. Protective immune responses are obtained by using saRNA, particularly VRP vectors as a prime and MVA vectors for boosting. Specifically, the present invention relates to genetically engineered (recombinant) VRP and MVA vectors that contain at least one heterologous nucleotide sequence encoding an antigenic determinant of an infectious virus (e.g., EBV).
Owner:BAVARIAN NORDIC AS

Immunization against group a streptococcus (GAS)

PCT designated stageWO2026021930A3Bacterial antigen ingredientsAntibacterial agentsAntigenGN - Glomerulonephritis
A composition comprising isolated Streptococcus pyogenes extracellular vesicles (EVs) suspended in a vehicle, for use in eliciting an adaptive immune response against group A streptococcus (GAS) in a subject. The EVs may comprise antigens MtsA, Spy_1228, PrsA1, PrsA2, SPy_0319 and / or GlnP. A composition comprising isolated S. pyogenes protein(s) MtsA, SPy_1228, PrsA1, PrsA2, GlnP, SPy_0319 and / or MalX. The compositions may be used for inducing protective immunity in a subject against a GAS infection, such as streptococcal pharyngitis, scarlet fever, impetigo, streptococcal meningitis, streptococcal sinusitis, necrotizing fasciitis, cellulitis, streptococcal toxic shock syndrome, rheumatic fever and post-streptococcal glomerulonephritis.
Owner:HENRIQUES NORMARK BIRGITTA

Ferritin nanoparticle vaccine for preventing giardia disease and preparation method thereof

PendingCN120943973AProtozoa antigen ingredientsAntibody mimetics/scaffoldsGiardiosisGiardia Infections
The invention provides a ferritin nanoparticle vaccine for preventing giardiasis and a preparation method thereof, and ferritin nanoparticles are used as a vaccine carrier to construct a subunit vaccine for preventing giardiasis. According to the vaccine, the stability and immunogenicity of the antigen are remarkably improved; and by utilizing the characteristics of the nanotechnology, the targeted delivery of the vaccine can be realized, so that the vaccine can act on immune cells more accurately, and the immune response level of the system is effectively improved. The vaccine has the characteristics of low cost, high safety and capability of inducing good protective immunity, and effectively controls giardia infection and propagation thereof.
Owner:JILIN UNIVERSITY

Recombinant protein vaccine for preventing and treating SARS-CoV-2 variants JN.1, BA.2. 86 and XBB pedigree, combined medicine and application

PendingCN119113096AImprove neutralization abilityStable and durable immune responseSsRNA viruses positive-senseViral antigen ingredientsHeterologous vaccineVaccination
The invention belongs to the field of medicines, and particularly relates to a recombinant protein vaccine for preventing and treating SARS-CoV-2 variants JN.1, BA.2. 86 and XBB pedigree, a combined medicine and application. In order to solve the problem that Aumitron JN.1, BA.2. 86 and XBB pedigree variants show significant immune escape and blot immune phenomena after previous vaccination and virus infection, the invention provides an XBB.1. 5 recombinant protein vaccine, which induces powerful body fluid, cell and mucous membrane immune responses to JN.1, BA.2. 86 and XBB pedigree variants by intramuscular and intranasal vaccination. Compared with homologous vaccine inoculation, the inactivated or mRNA vaccine is applied and then heterologous vaccine inoculation is carried out by using the vaccine, so that better immune response is obtained. And the vaccine induces effective protective immunity against the attack of the live Omitron EG.5.1 virus in vivo. Therefore, the XBB.1.5 vaccine disclosed by the invention has clinical use value.
Owner:WEST VAC BIOPHARMA CO LTD

Methods of manufacturing porcine endogenous retrovirus (PERV) free animal health vaccines

The invention provides a method of preparing a vaccine composition. The method includes infecting gene-edited porcine endogenous retrovirus (PERV) negative swine cells with a microorganism which expresses at least one protein antigen capable of inducing protective immunity in an animal against an infectious agent; culturing the infected cells in culture medium to propagate the microorganism; and harvesting the propagated microorganism from the culture medium to obtain a fraction comprising a PERV free antigen for use in immunizing an animal against the infectious agent.
Owner:ZOETIS SERVICES LLC

Recombinant protein vaccine for preventing and treating SARS-cov-2 variant JN.1, ba.2.86, and XBB lineages, combination drug and use

PCT designated stageWO2025189415A1DepsipeptidesAntiviralsHeterologous vaccineVaccination
The present invention relates to a recombinant protein vaccine for preventing and treating SARS-CoV-2 variant JN.1, BA.2.86, and XBB lineages, a combination drug, and a use. To address significant immune escape and immune imprinting phenomena observed with Omicron JN.1, BA.2.86 and XBB lineage subvariants following prior vaccination or virus infection, an XBB.1.5 recombinant protein vaccine is provided. This vaccine elicits potent humoral and cellular immune responses against currently circulating JN.1, BA.2.86, and XBB lineage variants. Compared with homologous vaccination, heterologous vaccination with this vaccine following administration of an inactivated or mRNA-based vaccine achieves superior immune responses. Moreover, the vaccine induces effective protective immunity against live Omicron EG.5.1 virus attack in vivo. Therefore, the monovalent XBB.1.5 vaccine has clinical use value.
Owner:WEST VAC BIOPHARMA CO LTD

Novel adjuvant subunit rabies virus vaccine as well as preparation method and application thereof

The invention provides a novel adjuvant subunit rabies virus vaccine as well as a preparation method and application thereof, the vaccine takes a rabies virus (RABV) glycoprotein extracellular domain prepared by a gene recombination technology as an antigen, and takes a combination of CpG oligodeoxynucleotide and QS21 as an adjuvant. A contrast experiment is carried out on the vaccine, an LNP-mRNA-G-H270P vaccine, a commercial inactivated vaccine and an aluminum adjuvant subunit vaccine, and the result shows that the vaccine can induce a remarkably higher RABV-G specific IgG antibody and virus neutralizing antibody titer, and the humoral immune response is superior to that of other vaccines; meanwhile, moderate and effective Th1 type cell immune response can be induced, so that protective immunity can be supported; 100% protection is achieved in a lethal RABV attack experiment, and the protection effect is equivalent to that of an mRNA vaccine and is remarkably superior to that of an aluminum adjuvant vaccine and a commercial inactivated vaccine. The vaccine provided by the invention has a controllable immune activation mechanism and relatively high safety, avoids the storage risk and excessive inflammatory response of a nucleic acid technology, and is a more reliable and universal choice in the current vaccine technology.
Owner:INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI

Attenuated salmonella synthesizing antigens for vaccinating against helicobacter pylori

Helicobacter pylori is a leading cause of gastric mucosal inflammation, peptic ulcers, and gastric adenocarcinoma. Emerging antimicrobial-resistant H. pylori has hampered the successful eradication of frequent chronic infections. Additionally, due to the absence of effective vaccines against H. pylori, a safe vaccine is highly demanded. Disclosed herein are innovative Protective Immunity Enhanced Salmonella Vaccine (PIESV) vector strains to deliver and express multiple H. pylori antigen genes. Immunization of mice with a vaccine delivering the HpaA, NapA (also termed Hp-NAP), UreA and UreB antigens, provided sterile protection against H. pylori SS1 infection in 7 out of 10 tested mice. Compared to the control groups that had received PBS or a PIESV with an empty vector, immunized mice exhibited specific and significant cellular recall responses and antigen-specific IgG2c, IgG1, total IgG and gastric IgA antibody titers. Importantly, the mice immunized with the vaccine candidate showed a significant reduction in a load of an unidentified Gram-positive rod-shaped bacteria in their stomach compared to the control groups. In conclusion, a Salmonella Typhimurium-based live vaccine delivering four antigens shows promise as a safe and effective vaccine against H. pylori infection.
Owner:UNIV OF FLORIDA RESEARCH FOUNDATION INC

DNA plasmid-launched live-attanuated vaccines for plus-sense singel stranded RNA

The invention generally relates to the development of immunogenic compositions comprising a DNA copy of at least one live attenuated plus-sense single-stranded RNA virus genome, such as the genome of a live-attenuated Zika vims (ZIKV), Japanese encephalitis virus (JEV) or yellow fever vims (YFV). The immunogenic compositions can be used for treating or conferring protective immunity against diseases related to plus-sense single-stranded RNA viruses, e.g. for affording prolonged immunoprotection against such viruses and protective immunity is conferred at low diseases, e.g., as low as 300 or 500 ng after administration of a single pLAV dosage.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST